Published in Autophagy on January 01, 2015
Combination of sorafenib and gadolinium chloride (GdCl3) attenuates dimethylnitrosamine(DMN)-induced liver fibrosis in rats. BMC Gastroenterol (2015) 0.78
Hepatic macrophages in liver fibrosis: pathogenesis and potential therapeutic targets. BMJ Open Gastroenterol (2016) 0.78
Liver macrophages in tissue homeostasis and disease. Nat Rev Immunol (2017) 0.78
Function of Autophagy in Nonalcoholic Fatty Liver Disease. Dig Dis Sci (2016) 0.76
Evolving Insights on Metabolism, Autophagy, and Epigenetics in Liver Myofibroblasts. Front Physiol (2016) 0.75
2,3,7,8 Tetrachlorodibenzo-p-dioxin-induced RNA abundance changes identify Ackr3, Col18a1, Cyb5a and Glud1 as candidate mediators of toxicity. Arch Toxicol (2016) 0.75
Adipocyte Fatty Acid Binding Protein Potentiates Toxic Lipids-Induced Endoplasmic Reticulum Stress in Macrophages via Inhibition of Janus Kinase 2-dependent Autophagy. Sci Rep (2017) 0.75
Autophagy in macrophages regulates the inflammasome and protects against liver injury. J Hepatol (2015) 0.75
The Cannabinoid Receptor 2 Protects Against Alcoholic Liver Disease Via a Macrophage Autophagy-Dependent Pathway. Sci Rep (2016) 0.75
Autophagy induced by AXL receptor tyrosine kinase alleviates acute liver injury via inhibition of NLRP3 inflammasome activation in mice. Autophagy (2016) 0.75
The role of autophagy in asparaginase-induced immune suppression of macrophages. Cell Death Dis (2017) 0.75
BBC3 in macrophages promoted pulmonary fibrosis development through inducing autophagy during silicosis. Cell Death Dis (2017) 0.75
Key Events Participating in the Pathogenesis of Alcoholic Liver Disease. Biomolecules (2017) 0.75
The Evolving Functions of Autophagy in Ocular Health: A Double-edged Sword. Int J Biol Sci (2016) 0.75
Tumor necrosis factor-inducible gene 6 protein ameliorates chronic liver damage by promoting autophagy formation in mice. Exp Mol Med (2017) 0.75
AMP-activated protein kinase regulates lipid metabolism and the fibrotic phenotype of hepatic stellate cells through inhibition of autophagy. FEBS Open Bio (2017) 0.75
Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature (2006) 24.39
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Autophagy: process and function. Genes Dev (2007) 15.21
Autophagy regulates lipid metabolism. Nature (2009) 13.33
A role for mitochondria in NLRP3 inflammasome activation. Nature (2010) 13.21
Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1beta production. Nature (2008) 11.39
Autophagy in immunity and inflammation. Nature (2011) 11.16
Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. Nat Immunol (2010) 9.02
Identification of a key pathway required for the sterile inflammatory response triggered by dying cells. Nat Med (2007) 7.25
An autophagy-enhancing drug promotes degradation of mutant alpha1-antitrypsin Z and reduces hepatic fibrosis. Science (2010) 6.47
Activation of autophagy by inflammatory signals limits IL-1β production by targeting ubiquitinated inflammasomes for destruction. Nat Immunol (2012) 4.72
CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nat Med (2006) 4.36
Hepatotoxicity and mechanism of action of haloalkanes: carbon tetrachloride as a toxicological model. Crit Rev Toxicol (2003) 4.25
Neutrophil depletion protects against murine acetaminophen hepatotoxicity. Hepatology (2006) 3.70
Autophagy reduces acute ethanol-induced hepatotoxicity and steatosis in mice. Gastroenterology (2010) 3.57
Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice. Gastroenterology (2010) 3.52
Scar-associated macrophages are a major source of hepatic matrix metalloproteinase-13 and facilitate the resolution of murine hepatic fibrosis. J Immunol (2007) 2.64
IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice. J Clin Invest (2012) 2.64
Evolving therapies for liver fibrosis. J Clin Invest (2013) 2.59
Kupffer cells promote hepatic steatosis via interleukin-1beta-dependent suppression of peroxisome proliferator-activated receptor alpha activity. Hepatology (2010) 2.53
Macrophage autophagy plays a protective role in advanced atherosclerosis. Cell Metab (2012) 2.48
Neutrophils contribute to ischemia/reperfusion injury in rat liver in vivo. FASEB J (1990) 2.41
IL-1α and IL-1β recruit different myeloid cells and promote different stages of sterile inflammation. J Immunol (2011) 2.25
Activation of autophagy protects against acetaminophen-induced hepatotoxicity. Hepatology (2011) 2.15
Autophagy releases lipid that promotes fibrogenesis by activated hepatic stellate cells in mice and in human tissues. Gastroenterology (2012) 2.11
Autophagy protects against active tuberculosis by suppressing bacterial burden and inflammation. Proc Natl Acad Sci U S A (2012) 2.10
Autophagy links inflammasomes to atherosclerotic progression. Cell Metab (2012) 2.08
Lack of interleukin-1α or interleukin-1β inhibits transformation of steatosis to steatohepatitis and liver fibrosis in hypercholesterolemic mice. J Hepatol (2011) 2.02
Autophagy suppresses age-dependent ischemia and reperfusion injury in livers of mice. Gastroenterology (2011) 1.96
Macroautophagy and chaperone-mediated autophagy are required for hepatocyte resistance to oxidant stress. Hepatology (2010) 1.91
Beneficial paracrine effects of cannabinoid receptor 2 on liver injury and regeneration. Hepatology (2010) 1.82
Phagocytosis of apoptotic bodies by hepatic stellate cells induces NADPH oxidase and is associated with liver fibrosis in vivo. Hepatology (2006) 1.71
Chronic plus binge ethanol feeding synergistically induces neutrophil infiltration and liver injury in mice: a critical role for E-selectin. Hepatology (2013) 1.58
Cell-specific PPARγ deficiency establishes anti-inflammatory and anti-fibrogenic properties for this nuclear receptor in non-parenchymal liver cells. J Hepatol (2013) 1.55
Monocytes and macrophages as cellular targets in liver fibrosis. Inflamm Allergy Drug Targets (2009) 1.52
Essential role for neutrophil recruitment to the liver in concanavalin A-induced hepatitis. J Immunol (2004) 1.49
Cellular mechanisms of tissue fibrosis. 5. Novel insights into liver fibrosis. Am J Physiol Cell Physiol (2013) 1.42
Cannabinoid CB2 receptors protect against alcoholic liver disease by regulating Kupffer cell polarization in mice. Hepatology (2011) 1.41
Functions of autophagy in hepatic and pancreatic physiology and disease. Gastroenterology (2011) 1.35
Autophagy: a multifaceted partner in liver fibrosis. Biomed Res Int (2014) 1.05
Liver fibrosis: a bidirectional model of fibrogenesis and resolution. QJM (2012) 1.03
Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med (2009) 10.21
Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology (2005) 9.39
Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol (2013) 5.64
CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nat Med (2006) 4.36
Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol (2008) 3.50
Structural biology of hepatitis C virus. Hepatology (2004) 3.40
The Cobas AmpliPrep-Cobas TaqMan real-time polymerase chain reaction assay fails to detect hepatitis C virus RNA in highly viremic genotype 4 clinical samples. Hepatology (2009) 3.08
Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology (2007) 3.08
Hepatitis C pharmacogenetics: state of the art in 2010. Hepatology (2011) 2.99
Rab27a regulates phagosomal pH and NADPH oxidase recruitment to dendritic cell phagosomes. Nat Cell Biol (2007) 2.69
Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection. J Infect Dis (2006) 2.55
IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. Hepatology (2006) 2.54
euHCVdb: the European hepatitis C virus database. Nucleic Acids Res (2006) 2.41
Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology (2005) 2.33
Phosphorylation of p47phox sites by PKC alpha, beta II, delta, and zeta: effect on binding to p22phox and on NADPH oxidase activation. Biochemistry (2002) 2.31
Antiviral strategies in hepatitis C virus infection. J Hepatol (2012) 2.25
Characterization of the dynamics of hepatitis B virus resistance to adefovir by ultra-deep pyrosequencing. Hepatology (2013) 2.24
Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication. Hepatology (2002) 2.21
M2 Kupffer cells promote M1 Kupffer cell apoptosis: a protective mechanism against alcoholic and nonalcoholic fatty liver disease. Hepatology (2013) 2.16
Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology (2005) 2.07
Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin. Gastroenterology (2006) 2.07
Daily cannabis use: a novel risk factor of steatosis severity in patients with chronic hepatitis C. Gastroenterology (2007) 1.94
Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. J Hepatol (2004) 1.92
A specific p47phox -serine phosphorylated by convergent MAPKs mediates neutrophil NADPH oxidase priming at inflammatory sites. J Clin Invest (2006) 1.92
Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely. J Hepatol (2012) 1.86
Overestimation and underestimation of hepatitis C virus RNA levels in a widely used real-time polymerase chain reaction-based method. Hepatology (2007) 1.83
Hepatitis C virus: virology, diagnosis and management of antiviral therapy. World J Gastroenterol (2007) 1.82
Beneficial paracrine effects of cannabinoid receptor 2 on liver injury and regeneration. Hepatology (2010) 1.82
Treatment of chronic hepatitis B virus infection in resource-constrained settings: expert panel consensus. Liver Int (2011) 1.75
Management of antiviral resistance in patients with chronic hepatitis B. Antivir Ther (2004) 1.72
Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase. Gastroenterology (2009) 1.69
Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms. PLoS One (2011) 1.69
The prolyl isomerase Pin1 acts as a novel molecular switch for TNF-alpha-induced priming of the NADPH oxidase in human neutrophils. Blood (2010) 1.68
Candida albicans impairs macrophage function and facilitates Pseudomonas aeruginosa pneumonia in rat. Crit Care Med (2009) 1.68
A comprehensive system for consistent numbering of HCV sequences, proteins and epitopes. Hepatology (2006) 1.65
Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response. Hepatology (2011) 1.62
Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C. Hepatology (2010) 1.61
Adaptor protein-3 in dendritic cells facilitates phagosomal toll-like receptor signaling and antigen presentation to CD4(+) T cells. Immunity (2012) 1.59
Hepatic fibrosis: molecular mechanisms and drug targets. Annu Rev Pharmacol Toxicol (2005) 1.58
EASL Clinical Practice Guidelines. J Hepatol (2008) 1.53
Mitochondrial respiratory chain and NAD(P)H oxidase are targets for the antiproliferative effect of carbon monoxide in human airway smooth muscle. J Biol Chem (2005) 1.50
Spontaneous recovery in acute human hepatitis C virus infection: functional T-cell thresholds and relative importance of CD4 help. J Virol (2007) 1.50
Efficacy and safety of adefovir dipivoxil 20 mg daily in HBeAg-positive patients with lamivudine-resistant hepatitis B virus and a suboptimal virological response to adefovir dipivoxil 10 mg daily. J Hepatol (2007) 1.49
Interferon-based therapy of hepatitis C. Adv Drug Deliv Rev (2007) 1.49
Adipose tissue macrophages: MR tracking to monitor obesity-associated inflammation. Radiology (2012) 1.49
Bilirubin decreases nos2 expression via inhibition of NAD(P)H oxidase: implications for protection against endotoxic shock in rats. FASEB J (2005) 1.49
Genetic background of hepatocyte cell lines: are in vitro hepatitis C virus research data reliable? Hepatology (2011) 1.48
Efficacy of serologic marker screening in identifying hepatitis B virus infection in organ, tissue, and cell donors. Gastroenterology (2008) 1.46
The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report. Liver Int (2009) 1.46
Comparison of hepatitis C virus NS5b and 5' noncoding gene sequencing methods in a multicenter study. J Clin Microbiol (2005) 1.45
Cellular mechanisms of tissue fibrosis. 5. Novel insights into liver fibrosis. Am J Physiol Cell Physiol (2013) 1.42
[Steasis and hepatitis C]. Gastroenterol Clin Biol (2003) 1.41
Cannabinoid CB2 receptors protect against alcoholic liver disease by regulating Kupffer cell polarization in mice. Hepatology (2011) 1.41
Induction of heme oxygenase-1 inhibits NAD(P)H oxidase activity by down-regulating cytochrome b558 expression via the reduction of heme availability. J Biol Chem (2004) 1.41
New virologic tools for management of chronic hepatitis B and C. Gastroenterology (2012) 1.41
Dynamics of hepatitis B virus resistance to lamivudine. J Virol (2006) 1.38
Alpha interferon inhibits hepatitis C virus replication in primary human hepatocytes infected in vitro. J Virol (2002) 1.35
Regulation of the phagocyte NADPH oxidase activity: phosphorylation of gp91phox/NOX2 by protein kinase C enhances its diaphorase activity and binding to Rac2, p67phox, and p47phox. FASEB J (2008) 1.33
Hepatitis C virus (HCV) genotype 1 subtype identification in new HCV drug development and future clinical practice. PLoS One (2009) 1.32
Elevated expression of osteopontin may be related to adipose tissue macrophage accumulation and liver steatosis in morbid obesity. Diabetes (2008) 1.30
International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. J Hepatol (2005) 1.30
ASK1-p38 MAPK-p47phox activation is essential for inflammatory responses during tuberculosis via TLR2-ROS signalling. Cell Microbiol (2007) 1.29
Chronic hepatitis B: preventing, detecting, and managing viral resistance. Clin Gastroenterol Hepatol (2008) 1.29
Cannabinoid CB2 receptor potentiates obesity-associated inflammation, insulin resistance and hepatic steatosis. PLoS One (2009) 1.25
The sphingosine 1-phosphate receptor S1P2 triggers hepatic wound healing. FASEB J (2007) 1.25
Recommendations for standardized nomenclature and definitions of viral response in trials of hepatitis C virus investigational agents. Hepatology (2012) 1.25
Basic residues in hypervariable region 1 of hepatitis C virus envelope glycoprotein e2 contribute to virus entry. J Virol (2005) 1.21
The epidermal growth factor receptor ligand amphiregulin participates in the development of mouse liver fibrosis. Hepatology (2008) 1.20
Hepatitis C virus serologic and virologic tests and clinical diagnosis of HCV-related liver disease. Int J Med Sci (2006) 1.19
Hepatitis C virus (HCV) protein expression enhances hepatic fibrosis in HCV transgenic mice exposed to a fibrogenic agent. J Hepatol (2012) 1.17
Association of caffeine intake and histological features of chronic hepatitis C. J Hepatol (2011) 1.17
Long term in vivo biotransformation of iron oxide nanoparticles. Biomaterials (2011) 1.16
Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C. J Rheumatol (2004) 1.16
Roles of peroxiredoxin II in the regulation of proinflammatory responses to LPS and protection against endotoxin-induced lethal shock. J Exp Med (2007) 1.16
Performance of version 2.0 of the Cobas AmpliPrep/Cobas TaqMan real-time PCR assay for hepatitis B virus DNA quantification. J Clin Microbiol (2010) 1.15
Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial. Hepatology (2013) 1.14
Potent anti-inflammatory and neuroprotective effects of TGF-beta1 are mediated through the inhibition of ERK and p47phox-Ser345 phosphorylation and translocation in microglia. J Immunol (2008) 1.13
Diagnosis and management of chronic viral hepatitis: antigens, antibodies and viral genomes. Best Pract Res Clin Gastroenterol (2008) 1.12
The cannabinoid receptor type 2 promotes cardiac myocyte and fibroblast survival and protects against ischemia/reperfusion-induced cardiomyopathy. FASEB J (2009) 1.12
Analysis of ribavirin mutagenicity in human hepatitis C virus infection. J Virol (2007) 1.10
Hepatitis C virus proteins induce lipogenesis and defective triglyceride secretion in transgenic mice. J Biol Chem (2009) 1.10
Hyperactivation of anandamide synthesis and regulation of cell-cycle progression via cannabinoid type 1 (CB1) receptors in the regenerating liver. Proc Natl Acad Sci U S A (2011) 1.09
Francisella acid phosphatases inactivate the NADPH oxidase in human phagocytes. J Immunol (2010) 1.07
Molecular epidemiology of hepatitis C virus subtype 3a in injecting drug users. J Med Virol (2006) 1.06
HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project). Gastroenterology (2007) 1.06
Heme oxygenase-1 is an antifibrogenic protein in human hepatic myofibroblasts. Gastroenterology (2003) 1.05
Reactive oxygen species and p47phox activation are essential for the Mycobacterium tuberculosis-induced pro-inflammatory response in murine microglia. J Neuroinflammation (2007) 1.05
Hepatitis C virus-induced hepatocellular steatosis. Am J Gastroenterol (2005) 1.05
Cannabinoid receptors as new targets of antifibrosing strategies during chronic liver diseases. Expert Opin Ther Targets (2007) 1.05